top of page
Browse by category
Search
TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in patients with acquired hypothalamic obesity
Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a...
Medicare and Medicaid will not expand coverage to anti-obesity medications
The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal to expand...
Confronting obesity on World Health Day: A call for a new standard of care
This World Health Day, it is time to confront obesity. Despite advances in obesity treatments, the obesity epidemic continues to...
International Diabetes Federation reports 250 million people are unaware they have diabetes
Nearly one in nine adults (589 million) are now living with diabetes with an estimated 252 million unaware they have the condition,...
Tehran Obesity Treatment Study identifies significant predictors of insufficient weight loss post-BMS
Researchers from Iran, reporting the latest outcomes from the Tehran Obesity Treatment Study, have reported older age, a higher baseline...
Where people shop for their food and the risk of obesity-related cancers
A team of researchers at the University of Connecticut have developed a novel tool to help understand consumer behaviour at the county...
Antag begins trial of AT-7687, a GIPR antagonist designed to address key gaps in obesity treatment
Antag Therapeutics has initiated its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent...
BariPredict: Class II obesity, younger age and concurrent depression are risk factors for eating disorders in potential bariatric patients
Outcomes from the BariPredict cohort have found that 65.8% prevalence of persons at risk of an eating disorder (ED) - opting for, but not...
MC4R Agonist bremelanotide co-administered with tirzepatide meets primary endpoint
Palatin Technologies’ BMT-801 Phase 2 obesity co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like...
Magnetic bipartition feasible, safe and effective in achieving incisionless, suture/staple-free duodeno-ileostomy
An innovative technique using a biofragmentable magnetic anastomosis system (BMAS) to effect magnetic duodeno-ileostomy (MagDI)...
Browse by tag
bottom of page